

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Lisdexamfetamine (Vyvanse)

Notes:

- Quantity Limits: Yes
- Adequate trial of a long acting agent is further defined as wearing off that is not resolved by increasing the dose, AND adding a short-acting agent OR increasing frequency to twice daily OR clinically significant side effects related to the dosage form that cannot be resolved by adjusting the dose or timing.

Non-formulary **lisdexamfetamine (Vyvanse)** will be covered on the prescription drug benefit when the following criteria are met:

For Binge Eating Disorder:

- Diagnosis of Binge Eating Disorder **-AND-**
- Prior adequate trial (6 weeks) and failure of 2 formulary Selective Serotonin Reuptake Inhibitors (SSRIs) unless contraindication, intolerance, or allergy **-AND-**
- Adequate trial** (7 days) of dextroamphetamine ER (Dexedrine Spansules), unless allergy to an inactive ingredient or history of substance use disorder **-OR-**
- Patient is already stable on drug

For attention-deficit/hyperactivity disorder (ADHD) or attention deficit disorder (ADD) in patients under 21 years of age:

- Diagnosis of ADHD or ADD **-AND-**
- Adequate trial** (7 days) of dextroamphetamine ER (Dexedrine Spansules), unless allergy to an inactive ingredient or history of substance use disorder **-OR-**
- Patient is already stable on drug.

For patients 21 years of age or older not currently taking Vyvanse:

- Diagnosis of ADHD or ADD **-AND-**
- Adequate trial** (7 days) of a methylphenidate product (methylphenidate or dexmethylphenidate) **-AND-**
- Adequate trial** (7 days) of amphetamine salt combo, unless allergy to an inactive ingredient **-AND-**
- Adequate trial** (7 days) of dextroamphetamine ER (Dexedrine Spansules), unless allergy to an inactive ingredient **-OR-**
- Past diagnosis or treatment for substance use disorder

For patients 21 years of age or older currently taking Vyvanse:

kp.org

Revised: 01/13/22
Effective: 03/03/22

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Lisdexamfetamine (Vyvanse)

- Diagnosis of ADHD or ADD **-AND-**
- Adequate trial** (7 days) of dextroamphetamine ER (Dexedrine Spansules), unless allergy to an inactive ingredient or history of substance use disorder
- **-OR-**
- Dose change only: patient meets current criteria and is already taking the drug

kp.org

Revised: 01/13/22
Effective: 03/03/22

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest